🟢 Nautilus Biotechnology is trading 6% up in pre-market after beating third-quarter EPS and revenue estimates

Nautilus Biotechnology is trading at $2.59, up 6.16%, after third-quarter EPS and revenue beat estimates.

• Third-quarter EPS was -$0.12 versus the -$0.14 estimate; revenue was $230,000 versus the $206,250 estimate. Results were released before market open on October 27, 2026.
• The company reported $0.2 million in quarterly revenue and reaffirmed anticipated instrument availability in mid-2027.
• Separately, it announced participation in an ARPA-H-funded consortium, with up to $6 million expected over the program’s duration.